Cassava Sciences Inc vs Clear Secure Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Clear Secure Inc trades at $46.98 (market cap $4.98B). The key difference: Clear Secure Inc is far larger — about 104.3× Cassava Sciences Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | YOU | |
|---|---|---|
Market Cap | $47.75M | $4.98B |
Sector | Health | Technology |
52-Week High | $4.64 | $62.36 |
52-Week Low | $0.87 | $29.61 |
Enterprise Value | -$34.93M | $4.13B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Clear Secure (YOU) trades at $47.31, down 7.63% over 24 hours, reflecting a bearish technical trend with support near $45. Fundamentally, the company reported strong Q2 2026 earnings of $0.49 per share, beating estimates, with revenue growth to $1.0 billion projected for 2026 and a net income margin of 14.78%. Recent news highlights expansion of its CLEAR1 platform and corporate membership launches, driving investor optimism despite recent price pressure.
The outlook is mixed: robust earnings beats and strategic initiatives support growth, but high valuation ratios (P/E of 32.62) and bearish technical signals pose risks. Analysts are divided with a 44% buy rating, suggesting cautious optimism amid volatility. Key risks include execution challenges and competitive pressures in identity verification services.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →